Literature DB >> 12738239

The tumor microenvironment: focus on myeloma.

William S Dalton1.   

Abstract

A wide variety of cellular responses that may afford tumor cells drug-tolerance characteristics. Overexpression of plasma membrane efflux pumps, up-regulation of anti-apoptosis factors, down-regulation of proapoptosis factors, subcellular redistribution of drug targets, and up-regulation of detoxifying enzymes are just a few known mechanisms of cancer cell resistance. In addition to these individual cell adaptations, cellular drug resistance also appears to be mediated by the binding of tumor cells to extracellular matrix (ECM) proteins. Cell adhesion-mediated drug resistance (CAM-DR) is particularly relevant in hematologic malignancies such as multiple myeloma, where myeloma cells localize in the bone marrow and interact with stroma and stromal cells, initiating the production of proteins that stimulate or support tumor survival. Thus, CAM-DR provides a plausible explanation for the protective mechanisms associated with myeloma cell adhesion and demonstrates that the tumor microenvironment may hold the key to elucidating how tumor cells resist chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738239     DOI: 10.1016/s0305-7372(03)00077-x

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  19 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Authors:  Chad C Bjorklund; Wencai Ma; Zhi-Qiang Wang; R Eric Davis; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Jatin J Shah; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

Review 3.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 4.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 5.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

6.  Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells.

Authors:  Elizabeth Hernandez Marin; Hana Paek; Mei Li; Yesung Ban; Marie Katie Karaga; Rangaiah Shashidharamurthy; Xinyu Wang
Journal:  Invest New Drugs       Date:  2018-11-22       Impact factor: 3.850

Review 7.  Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.

Authors:  Bumsoo Han; Chunjing Qu; Kinam Park; Stephen F Konieczny; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

Review 8.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

9.  Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip.

Authors:  Kyeonggon Shin; Brett S Klosterhoff; Bumsoo Han
Journal:  Mol Pharm       Date:  2016-06-10       Impact factor: 4.939

10.  Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

Authors:  Jaehyup Kim; Ryan A Denu; Bridget A Dollar; Leah E Escalante; Justin P Kuether; Natalie S Callander; Fotis Asimakopoulos; Peiman Hematti
Journal:  Br J Haematol       Date:  2012-05-15       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.